Patient P-02168

Synthetic patientMETA-24 · Day 176 · 65–74 · F · baseline S15Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

65%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S15
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −23% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 71 GI-04 recommended — GI Support Protocol GI-04
Day 72 Patient accepted — Started GI-04 in the companion
Day 80 GI symptom burden −27% vs expected — GI Support Protocol GI-04
Day 86 Tolerance state changed — Unstable → Improving
Day 88 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 89 ME-01 recommended — Monitoring Escalation ME-01
Day 90 Patient accepted — Started ME-01 in the companion
Day 93 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 88.

Primary contributors, last 14 days

GI instability+8
Toxicity-5
Treatment adherence+4

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −23%
GI Support Protocol GI-04Day 71
Result: symptom burden −27%
Monitoring Escalation ME-01Day 89
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Clinician Review CR-01

74%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 58 and rising
- WearableSleep 6.0 h, below personal baseline
Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
- WearableHRV 33 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 78 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.1 · butyrate capacity 33/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 5.7 h
Steps: 6,103
Resting HR: 78 bpm

Daily log: GI score 58, nutritional resilience 45, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02255	52%	S14	GI-04	improved	43
P-02018	50%	S01	GI-04	improved	46
P-02328	50%	S14	GI-04	improved	42
P-02106	48%	S14	GI-04	improved	44
P-02108	48%	S14	GI-04	improved	43
P-02002	47%	S14	GI-04	improved	47
P-02241	46%	S09	GI-04	improved	56
P-02401	46%	S14	GI-04	improved	49
P-02574	46%	S14	ME-01	improved	45
P-02628	45%	S14	SC-12	improved	47
P-02132	44%	S14	SC-12	improved	40
P-02149	43%	S14	GI-04	improved	50